What is the recommended iron sucrose regimen for a patient with ongoing bleeding and iron deficiency anemia, considering their kidney function and potential underlying medical conditions?

Iron Sucrose Regimen for Ongoing Bleeding

For patients with ongoing bleeding and iron deficiency anemia, intravenous iron sucrose should be administered at 200 mg per dose over 10 minutes, repeated 2-3 times weekly, with a maximum weekly dose of 500 mg, until iron stores are replenished or hemoglobin targets are achieved. 1, 2

Dosing Protocol

Standard Dosing Parameters

• Maximum single dose: 200 mg administered as IV push over 5-10 minutes or as infusion over 30 minutes 3, 4, 2
• Maximum weekly dose: 500 mg to prevent dose-related anaphylactoid reactions 5, 2
• Frequency: 2-3 times per week until total calculated iron deficit is replaced 3, 5

Total Iron Replacement Calculation

For patients with ongoing bleeding, use simplified dosing based on hemoglobin and body weight 6:

• Hemoglobin 10-12 g/dL (women) or 10-13 g/dL (men):
  • Body weight <70 kg: 1000 mg total
  • Body weight ≥70 kg: 1500 mg total
• Hemoglobin 7-10 g/dL:
  • Body weight <70 kg: 1500 mg total
  • Body weight ≥70 kg: 2000 mg total 6

This translates to 5-10 doses of 200 mg given over 2.5-5 weeks for most patients 5, 2

Administration Guidelines

Preparation and Infusion

• No test dose required for iron sucrose, unlike iron dextran 5, 2
• Administer undiluted as 100-200 mg IV push over 5-10 minutes 5, 7
• Alternative: dilute in 100 mL of 0.9% normal saline and infuse over 30 minutes 2
• For 300-500 mg doses (not recommended as single dose): dilute in maximum 250 mL 0.9% NaCl over longer infusion time 2

Monitoring During Administration

• Start infusion slowly for first 5 minutes to assess for reactions 2
• Monitor vital signs during and after infusion 2
• Observe patient for 15-60 minutes post-infusion 2
• Have resuscitation equipment, IV epinephrine, diphenhydramine, and trained personnel immediately available 2

Special Considerations for Ongoing Bleeding

When to Use IV Iron Over Oral Iron

Intravenous iron sucrose is preferred as first-line therapy in patients with ongoing bleeding because 6, 1:

• Oral iron cannot maintain adequate stores in the setting of active blood loss 5
• IV iron provides more rapid hemoglobin response than oral preparations 6, 8
• Ongoing bleeding creates functional iron deficiency that oral iron cannot overcome 5

Specific Clinical Scenarios

Portal Hypertensive Gastropathy with Ongoing Bleeding:

• Initially attempt oral iron, but switch to IV iron sucrose if no response 1
• Continue IV iron replacement alongside treatment of portal hypertension with non-selective β-blockers 1

Inflammatory Bowel Disease with Active Bleeding:

• IV iron is first-line when disease is clinically active 6
• Active inflammation impairs oral iron absorption and may be exacerbated by luminal iron 6

Chronic Kidney Disease with Blood Loss:

• Regular small doses weekly (100 mg 2-3 times/week) prevent iron deficiency better than intermittent large doses 5
• Target transferrin saturation ≥20% and ferritin ≥100 ng/mL 5

Contraindications and Safety

Absolute Contraindications

• Active bacteremia - withhold until infection controlled 1, 2
• Known hypersensitivity to iron sucrose 2

Important Safety Notes

• Chronic infection alone is not an absolute contraindication if risk/benefit favors treatment 1, 2
• Hypersensitivity reactions occur in only 0.5% of patients, significantly lower than iron dextran 1, 2
• True anaphylaxis is very rare; most reactions are complement activation-related pseudo-allergy (infusion reactions) 1

Common Adverse Effects

• Hypotension, nausea, vomiting, diarrhea (most frequent) 2
• Hypophosphatemia occurs in only 1% of iron sucrose patients (compared to 58% with ferric carboxymaltose) 2
• Monitor serum phosphate if multiple high-dose infusions planned 2

Response Assessment and Targets

Expected Response Timeline

• Hemoglobin increase evident after 3 doses (approximately 1-2 weeks) 7
• Sustained elevation persists 5 weeks after final dose 7
• Transferrin saturation and ferritin levels increase significantly and remain elevated 7

Treatment Targets

• Hemoglobin: 11-12 g/dL 5
• Transferrin saturation: ≥20% 5
• Serum ferritin: ≥100 ng/mL 5

When Response is Inadequate

If hemoglobin remains below target despite achieving ferritin ≥100 ng/mL and transferrin saturation ≥20%, consider 5:

1. Administer 1000 mg IV iron over 8-10 weeks (5 doses of 200 mg twice weekly)
2. Assess response at constant erythropoietin dose
3. If no response after first course, repeat second 1000 mg course
4. If still no response but iron parameters increase, reduce to maintenance dosing

Critical Pitfalls to Avoid

• Do not exceed 200 mg single dose - higher doses (400-500 mg) have unacceptably high adverse event rates 9
• Do not exceed 500 mg per week - dose-related reactions increase with higher weekly totals 2, 9
• Do not administer during active bacteremia - defer until infection controlled 1, 2
• Do not give test dose - this is unnecessary for iron sucrose and delays treatment 2, 7
• Do not use 2-hour infusions routinely - 10-minute bolus dosing is equally safe and more convenient 4